FCGR2A and neoplasm: Tumour-bearing mice were treated with mouse-reactive surrogate anti-TIGIT monoclonal antibodies bearing varying Fc domains: mIgG2a-LALAPG (Fc inert), which lacks effector function26, mIgG2b, which engages activating and inhibitory FcγR, and mIgG2a, which preferentially engages activating FcγR27.